Trials / Completed
CompletedNCT03751163
Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma
Randomized, Controlled, Double-blind Study of Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Fakultas Kedokteran Universitas Indonesia · Academic / Other
- Sex
- Female
- Age
- 21 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This study assess the effectiveness of oral tranexamic acid in combination with hydroquinone cream in the treatment of melasma.
Detailed description
Hydroquinone (HQ) is considered the gold standard depigmenting agent for melasma, nevertheless, many patients are recalcitrant to this treatment. Recent studies have shown that tranexamic acid, a plasmin inhibitor, can prevent UV-induced pigmentation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tranexamic Acid Oral Product | Encapsulated tranexamic acid 250 mg |
| DRUG | Hydroquinone 4% Cream | Hydroquinone 4% Cream |
| OTHER | Sunscreen | Sunscreen SPF 30 |
| DEVICE | Placebo | Encapsulated placebo |
Timeline
- Start date
- 2016-03-16
- Primary completion
- 2017-04-02
- Completion
- 2017-04-02
- First posted
- 2018-11-23
- Last updated
- 2018-11-26
Source: ClinicalTrials.gov record NCT03751163. Inclusion in this directory is not an endorsement.